The Risk of Developing Long COVID in Patients With Inflammatory Bowel Diseases: Do Immunosuppressive Drugs Matter?

Clin Gastroenterol Hepatol. 2023 Jul;21(7):1971-1972. doi: 10.1016/j.cgh.2022.12.030. Epub 2023 Jan 13.

Authors

Arno R Bourgonje¹, Antonius T Otten¹

Affiliation

¹ Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.

PMID: 36642294
DOI: 10.1016/j.cgh.2022.12.030

No abstract available

Publication types

Letter
Comment

MeSH terms

COVID-19*
Humans
Immunosuppressive Agents / adverse effects
Inflammatory Bowel Diseases* / chemically induced
Inflammatory Bowel Diseases* / complications
Inflammatory Bowel Diseases* / drug therapy
Post-Acute COVID-19 Syndrome

Substances

Immunosuppressive Agents